SG11202011717UA - Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies - Google Patents

Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies

Info

Publication number
SG11202011717UA
SG11202011717UA SG11202011717UA SG11202011717UA SG11202011717UA SG 11202011717U A SG11202011717U A SG 11202011717UA SG 11202011717U A SG11202011717U A SG 11202011717UA SG 11202011717U A SG11202011717U A SG 11202011717UA SG 11202011717U A SG11202011717U A SG 11202011717UA
Authority
SG
Singapore
Prior art keywords
eradication
monoclonal antibodies
bacterial biofilm
amyloid monoclonal
amyloid
Prior art date
Application number
SG11202011717UA
Inventor
Cagla Wilson
Scott Dessain
Original Assignee
Univ Temple
Lankenau Institute Of Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Lankenau Institute Of Medical Res filed Critical Univ Temple
Publication of SG11202011717UA publication Critical patent/SG11202011717UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
SG11202011717UA 2018-05-25 2019-05-24 Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies SG11202011717UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676390P 2018-05-25 2018-05-25
PCT/US2019/033897 WO2019226978A1 (en) 2018-05-25 2019-05-24 Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies

Publications (1)

Publication Number Publication Date
SG11202011717UA true SG11202011717UA (en) 2020-12-30

Family

ID=68617225

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011717UA SG11202011717UA (en) 2018-05-25 2019-05-24 Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies

Country Status (12)

Country Link
US (2) US11897942B2 (en)
EP (1) EP3802572A4 (en)
JP (1) JP2021525798A (en)
KR (1) KR20210095998A (en)
CN (1) CN112805296A (en)
AU (1) AU2019274591A1 (en)
BR (1) BR112020024048A2 (en)
CA (1) CA3101680A1 (en)
IL (1) IL278977A (en)
MX (1) MX2020012727A (en)
SG (1) SG11202011717UA (en)
WO (1) WO2019226978A1 (en)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660537A2 (en) * 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
US20050214318A1 (en) * 2003-10-23 2005-09-29 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on fusion protein
WO2005049802A2 (en) * 2003-11-14 2005-06-02 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
US20090156471A1 (en) 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
CA2740440A1 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
US8734795B2 (en) * 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
US20120190566A1 (en) * 2009-03-25 2012-07-26 Susan Lindquist Compositions and methods for inhibiting biofilms
WO2011014693A2 (en) 2009-07-29 2011-02-03 Whitehead Institute For Biomedical Research Bacteriophages expressing amyloid peptides and uses thereof
EP2552944B1 (en) * 2010-03-29 2019-08-14 University Of Southern California Compositions and methods for the removal of biofilms
US20120087860A1 (en) * 2010-05-24 2012-04-12 Marek Malecki Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags
US20130115257A1 (en) * 2010-07-08 2013-05-09 Katholieke Universiteit Leuven Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
CA2824389A1 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CN103797029B (en) * 2011-05-17 2016-08-17 洛克菲勒大学 Human immunodeficiency virus neutralizing antibody and using method thereof
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
US9814756B2 (en) 2012-06-15 2017-11-14 Temple University—Of the Commonwealth System of Higher Education Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium
US20150291991A1 (en) * 2012-11-16 2015-10-15 President And Fellows Of Harvard College Methods and compositions relating to amyloidogenic polypeptides
US20160194384A1 (en) * 2014-06-12 2016-07-07 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2015133882A1 (en) * 2014-03-07 2015-09-11 사회복지법인 삼성생명공익재단 Scfv antibody library, method for preparing same, and scfv antibody screening method using same
WO2016073963A1 (en) * 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
RU2767357C2 (en) * 2016-06-14 2022-03-17 Ксенкор, Инк. Bispecific checkpoint inhibitors antibodies

Also Published As

Publication number Publication date
KR20210095998A (en) 2021-08-04
EP3802572A1 (en) 2021-04-14
CN112805296A (en) 2021-05-14
MX2020012727A (en) 2021-06-15
US11897942B2 (en) 2024-02-13
CA3101680A1 (en) 2019-11-28
JP2021525798A (en) 2021-09-27
IL278977A (en) 2021-01-31
US20210122809A1 (en) 2021-04-29
US20220227846A1 (en) 2022-07-21
BR112020024048A2 (en) 2021-02-17
EP3802572A4 (en) 2022-03-23
WO2019226978A1 (en) 2019-11-28
AU2019274591A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL279235A (en) Dll3-cd3 bispecific antibodies
IL280780A (en) Anti-tigit antibodies
IL279356A (en) Il-11 antibodies
IL279352A (en) Il-11ra antibodies
IL280013A (en) Anti-il36r antibodies
IL278010A (en) Galectin-10 antibodies
IL289112A (en) Anti-tigit antibodies
IL282756A (en) Humanized anti-sirpα antibodies
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
IL291068A (en) Anti-cd73 antibodies
IL284584A (en) Anti-tigit antibodies
IL283476A (en) Single domain antibodies against cll-1
IL282355A (en) Exosome-targeting bispecific antibodies
EP3893931A4 (en) Methods of using anti-trem2 antibodies
IL281594A (en) Anti-klrg1 antibodies
GB201905150D0 (en) Ant-ige antibodies
GB201806084D0 (en) Antibodies
IL276937A (en) Use of an anti-p-selectin antibody
GB201917480D0 (en) Antibodies
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201900732D0 (en) Antibodies
IL278977A (en) Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
IL289160A (en) Anti-angpt2 antibodies
GB202108319D0 (en) Single domain antibodies